Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.
about
Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic ReviewHarnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosisInfluence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusHIV infection and older Americans: the public health perspectiveArterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and TatThe effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialCD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatoryImmuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in EuropeHIV-derived ssRNA binds to TLR8 to induce inflammation-driven macrophage foam cell formationAssociation of low level viremia with inflammation and mortality in HIV-infected adultsThe CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recoveryCardiovascular Complications of HIV in Endemic Countries.Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individualsInitiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level.Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil.When to start antiretroviral therapyPro-atherogenic shear stress and HIV proteins synergistically upregulate cathepsin K in endothelial cells.A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers.Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic ControllersCytomegalovirus-specific responses of CD38⁺ memory T cells are skewed towards IFN-γ and dissociated from CD154 in HIV-1 infectionHIV gp120 induces endothelial dysfunction in tumour necrosis factor-alpha-activated porcine and human endothelial cellsFunctional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion.Large vessel adventitial vasculitis characterizes patients with critical lower limb ischemia with as compared to without human immunodeficiency virus infectionMutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation.Glycoproteomic study reveals altered plasma proteins associated with HIV elite suppressors.Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS productionPhosphodiesterase 8a supports HIV-1 replication in macrophages at the level of reverse transcriptionBiomarkers and HIV-associated cardiovascular disease.Impaired distensibility of ascending aorta in patients with HIV infectionChanges in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infectionTranscriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllersTen year trends in community HIV viral load in Barbados: implications for treatment as prevention.Immunologic basis of cardiovascular disease in HIV-infected adults.HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.Immune dysregulation and vascular risk in HIV-infected patients: implications for clinical care.Cardiovascular implications from untreated human immunodeficiency virus infection.
P2860
Q26774828-783DA376-080F-498E-AB68-74F998F161A1Q26828443-B456266A-7051-4DF0-A3FB-20C8ADDF5042Q26851535-2C20C248-8096-4F18-B7F5-9E0BE4704BC0Q26858824-67E8F1CB-1D68-410A-973E-56CDBD2E16F1Q27026486-97028423-91A7-4A11-B1A9-A0F42CCF2240Q28080948-D3B2EFAB-B0A9-467F-BEF9-3E89D16B449AQ28475076-8034FBC0-8DAB-4A74-8175-098DE21341FFQ28477861-04BB2D94-B667-4C4C-96CD-02CDF754739CQ28539369-F6221DBE-6DF5-49A6-BC21-7AA1D3E0BEF5Q28541572-969C867D-2941-4B45-A74E-2041B3FB9DFDQ28743237-9EE49BEC-425F-4A8B-BADB-1BA0EB694B7BQ29307877-8649840C-CA02-4B7F-8977-E907A3A0C85FQ30244655-B1518D9C-BF35-4279-96F2-4D2ABE76FF25Q30362489-B01C38D9-837D-4CDE-8634-C6AF57B892ACQ30366554-1D081236-BD85-494D-826A-0A74B37E8119Q33649200-156BB299-3225-417A-B979-834752CC8915Q33745355-658E04A5-EB62-4AF5-8F5C-29B1540FB655Q33755753-C5BB4A20-162F-40C3-B963-0BA6FA2E3A15Q33799012-DECA38BA-13F3-44A6-8BC4-E96A2F702473Q33807792-58204A91-5081-478F-A68B-A697E517B194Q33815728-BF078504-24EA-474E-83DE-93B28E1E204BQ33828507-73C7F1D9-8C59-437F-A7C1-D42C51CAFB24Q33943390-853DDB0B-FDFF-447A-8247-CA3F3ADC9B97Q33954940-CFB4CA64-F15A-4518-94E4-E744B438BC0EQ33987485-462EA3D1-1064-4EF0-81C2-AC7303BB3653Q34110470-F7924B0E-88C3-4DE6-8DD3-CBA2C3C76FFAQ34146122-AC73E8A8-973B-4DB0-9F2E-F71579331D38Q34284388-2A195145-4303-428C-9FAD-033B3C5B224DQ34292033-ED66BF57-675B-4F48-8F33-FA3C8801A1FFQ34309051-D9929D91-45EC-4D63-B0BA-4F053F2937BEQ34335486-179027B8-B920-4145-BD5E-0820DC67AACAQ34356622-31AA7C28-4472-48CE-9CEF-0ECA90CC39CDQ34423991-8DB79CA7-69CC-43D3-8C66-8F39B1CDA9F8Q34557631-F50321BE-DE99-488B-B9B2-03D63E82562CQ34625953-5FD2C3D3-0C1F-4131-97CA-AC3BB1E620C3Q34631863-1F25E83C-C389-48EF-BD9D-2CDC897EF52BQ34638205-6DA926B5-5383-471A-A842-5FB94A7815D7Q34699130-69C33179-3991-4689-9FBD-B8C5005028A6Q34764372-5CADD8B0-8B7E-44C4-97C1-A1D29211FF17Q34793193-9AB68F78-A306-496F-90B7-068C907B3AB0
P2860
Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of viral replication, ant ...... IV-associated atherosclerosis.
@en
Role of viral replication, ant ...... IV-associated atherosclerosis.
@nl
type
label
Role of viral replication, ant ...... IV-associated atherosclerosis.
@en
Role of viral replication, ant ...... IV-associated atherosclerosis.
@nl
prefLabel
Role of viral replication, ant ...... IV-associated atherosclerosis.
@en
Role of viral replication, ant ...... IV-associated atherosclerosis.
@nl
P2093
P2860
P921
P1433
P1476
Role of viral replication, ant ...... IV-associated atherosclerosis.
@en
P2093
Amanda Schnell
Jeffrey N Martin
Peter Ganz
Peter W Hunt
Priscilla Y Hsue
Rebecca Hoh
S Craig Kalapus
P2860
P304
P356
10.1097/QAD.0B013E32832B514B
P407
P577
2009-06-01T00:00:00Z